Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Ohtuvayre Prior Auth Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Ohtuvayre (ensifentrine) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and Medicare Part B or Part D benefit review for Ohtuvayre maintenance treatment of COPD in eligible adults, including initial coverage and reauthorization.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyOhtuvayre (ensifentrine) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization records documenting the COPD diagnosis, FEV1 of 30%–70%, required LABA/LAMA-based therapy failure, patient age, and pulmonologist involvement.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    30–70%FEV1 range
    18+Minimum age
    6 monthsPrior therapy lookback
    4 weeksRequired therapy duration
    1 year / 2 years

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Authorization duration
    3 mgBilling unit

    Coverage Criteria

    Initial Therapy

    Covered for the FDA-approved indication when all initial criteria are met.

    Initial therapy

    • Covered indication: Maintenance treatment of chronic obstructive pulmonary disease (COPD).FDA-approved indication
    • Disease severity: The patient has moderate-to-severe COPD, defined as an FEV1 between 30% and 70%.FEV1 30%-70%
    • Prior therapy failure: The patient has tried and failed dual or triple therapy within the past six months that included LABA/LAMA therapy, such as Trelegy Ellipta, Anoro Ellipta, or Stiolto Respimat.Within the past six months

      Failure means no improvement, worsening of the condition, or intolerance after consistent use at maximum dosages for at least four weeks.

    • Adult age: The patient is at least 18 years of age.18 years or older
    • Prescriber qualification: The prescriber is a pulmonologist or has consulted a pulmonologist.Pulmonologist involvement

    Continuation Therapy

    Reauthorization requires documented clinical benefit with Ohtuvayre compared with baseline. At least one qualifying response must be documented.

    Documented clinical benefit

    • Symptom improvement: The patient has a decrease in symptoms with Ohtuvayre compared with baseline.Decreased symptoms
    • Lung-function improvement: The patient has improvement in lung function with Ohtuvayre compared with baseline.Improved lung function
    • Exacerbation reduction: The patient has reduced COPD exacerbations with Ohtuvayre compared with baseline.Reduced COPD exacerbations

    Ohtuvayre must not be used in combination with roflumilast.

    Coding and Coverage Parameters

    HCPCS Description Billing Units/How SuppliedHCPCSCovered
    J7601Ohtuvayre (ensifentrine); Billing unit: 3 mg
    FEV1
    Required FEV1 range30% to 70%
    Lower limit30% predicted FEV1
    Upper limit70% predicted FEV1
    Required therapy trial duration
    Minimum trial durationAt least 4 weeks
    Use requirementTherapy must be used consistently
    Dosing requirementAt maximum dosages

    Provider Requirements and Decision Points

    Prior Authorization

    Benefit Eligibility and Prior Authorization Review

    Prior authorization review is required for Ohtuvayre (ensifentrine), including diagnosis and administration review to determine whether coverage is available under the Medicare Part B or Part D benefit.

    • Covered use: maintenance treatment of chronic obstructive pulmonary disease (COPD).
    Note

    Authorization Duration

    When approved, Ohtuvayre is authorized for one year for an initial request and two years for reauthorization. Dosing must follow FDA-approved labeling or accepted standards of medical practice.

    • Initial authorization: 1 year
    • Reauthorization: 2 years

    Background

    Ohtuvayre (ensifentrine) is a nebulized phosphodiesterase inhibitor that inhibits PDE3 and PDE4. The policy covers its FDA-approved indication for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

    Policy Definitions

    Moderate-to-severe COPD
    DefinitionCOPD with an FEV1 between 30% and 70%
    Lower FEV1 limit30%
    Upper FEV1 limit70%
    Failure
    Failure meansNo improvement, worsening of the condition, or intolerance
    Trial requirementTherapy must be tried consistently at maximum dosages
    Adequate trial durationAt least 4 weeks

    Ohtuvayre Initial Authorization

    Ohtuvayre Initial Authorization

    Initial coverage requires all specified clinical, prior-therapy, age, and prescriber criteria.

    Initial Ohtuvayre criteria

    • FDA-approved indication: Ohtuvayre is requested for the maintenance treatment of chronic obstructive pulmonary disease (COPD).FDA-approved indication
    • Moderate-to-severe COPD: The patient has moderate-to-severe COPD defined by an FEV1 between 30% and 70%.FEV1 30%-70%
    • Qualifying prior therapy: The patient has tried and failed dual or triple therapy within the past six months that included LABA/LAMA therapy, such as Trelegy Ellipta, Anoro Ellipta, or Stiolto Respimat.

    Ohtuvayre Reauthorization

    Ohtuvayre Reauthorization

    Reauthorization requires documentation of clinical benefit with Ohtuvayre compared with baseline.

    Clinical response

    • Decreased symptoms: Documentation shows a decrease in symptoms with Ohtuvayre compared with baseline.Decreased symptoms
    • Improved lung function: Documentation shows improvement in lung function with Ohtuvayre compared with baseline.Improved lung function
    • Reduced exacerbations: Documentation shows reduced COPD exacerbations with Ohtuvayre compared with baseline.

    Required Prior Therapy

    StepRequired therapyExamplesTrial periodFailure definition
    1Trial and failure of dual or triple therapy that includes LABA/LAMA therapyTrelegy Ellipta; Anoro Ellipta; Stiolto RespimatWithin the past six months; maximum dosages for at least four weeks consistentlyNo improvement, worsening of the condition, or intolerance
    Policy Summary
    PayerGold Coast Health Plan
    PolicyOhtuvayre (ensifentrine) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization records documenting the COPD diagnosis, FEV1 of 30%–70%, required LABA/LAMA-based therapy failure, patient age, and pulmonologist involvement.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Coverage ParametersProvider Requirements and Decision PointsBackgroundPolicy DefinitionsOhtuvayre Initial AuthorizationOhtuvayre ReauthorizationRequired Prior Therapy
    Prior therapy lookback
    Required lookback periodWithin the past six months
    Therapy evaluatedDual or triple therapy including LABA/LAMA therapy
    ExamplesTrelegy Ellipta, Anoro Ellipta, or Stiolto Respimat
    Minimum age
    Minimum patient ageAt least 18 years
    Eligibility groupAdult patients
    DocumentationPatient age must be included in the initial request records
    Step Therapy

    Required LABA/LAMA-Based Therapy Trial

    The patient must have a documented trial and failure of dual or triple therapy during the past six months that included LABA/LAMA therapy before initial Ohtuvayre approval.

    • Examples include Trelegy Ellipta, Anoro Ellipta, and Stiolto Respimat.
    • Failure means no improvement, worsening of the condition, or intolerance after use at maximum dosages for at least four weeks consistently.

    Unsupported block type: documentation

    Unsupported block type: documentation

    Note

    Benefit and Administration Information

    Provide diagnosis and administration information for benefit review. Gold Coast Health Plan will determine whether the request is payable under Medicare Part B or Part D.

    • Ohtuvayre is indicated for maintenance treatment of COPD.
    • HCPCS: J7601 — Ohtuvayre (ensifentrine); billing unit: 3 mg.
    • Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document.
    Denial Risk

    Avoid Concomitant Roflumilast Use

    Ohtuvayre must not be used in combination with roflumilast. Requests for concomitant use may be denied.

    • Avoid concurrent Ohtuvayre and roflumilast therapy.
    Denial Risk

    Initial Clinical Criteria Not Met

    An initial request may be denied when the required clinical criteria are not met or the supporting records are incomplete.

    • COPD is not documented as moderate-to-severe with an FEV1 between 30% and 70%.
    • Required dual or triple therapy including a LABA/LAMA was not tried and failed within the past six months, or the documented trial did not meet the maximum-dose and four-week consistency requirements.
    • Patient is younger than 18 years of age.
    • The prescriber has not prescribed in consultation with, or is not, a pulmonologist.
    • Ohtuvayre is requested in combination with roflumilast.
    Denial Risk

    Insufficient Response for Reauthorization

    Reauthorization may be denied when the submitted records do not demonstrate an adequate response to Ohtuvayre compared with baseline.

    • No documented decrease in symptoms.
    • No documented improvement in lung function.
    • No documented reduction in COPD exacerbations.
    • Documentation does not establish clinical benefit in any of these areas compared with baseline.
    Within the past six months

    Failure means no improvement, worsening of the condition, or intolerance after consistent use at maximum dosages for at least four weeks.

  1. Age requirement: The patient is at least 18 years of age.18 years or older
  2. Pulmonologist involvement: The prescriber is a pulmonologist or has consulted a pulmonologist.Pulmonologist involvement
  3. Reduced COPD exacerbations